AndhraNews.net
Home » Features » Health » Peripheral Vascular Disease

Peripheral Vascular Disease


About Peripheral Vascular Disease

Peripheral vascular disease (PVD), also known as peripheral artery disease (PAD) or peripheral artery occlusive disease (PAOD), includes all diseases caused by the obstruction of large arteries in the arms and legs; and it also includes a subset of diseases classified as microvascular diseases resulting from episodal narrowing of the arteries(raynauds), or widening thereof(erythromelalgia) i.e. vascular spasms. PVD can result from atherosclerosis, inflammatory processes leading to stenosis, an embolism, or thrombus formation. It causes either acute or chronic ischemia (lack of blood supply), typically of the legs.

PCD is one of the eight conditions for a Chronic kidney disease risk.

Diabetes makes people vulnerable to PVD.

Peripheral Vascular Disease in News

Hansen Medical(R) Announces First Shipment of Magellan(TM) Mobility in the U.S.
Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced the shipment of the first Magellan Mobility Package for the Magellan Robotic System to the Miami Cardiac & Vascular Institute in Miami, FL, part of Baptist Health South Florida. MCVI is the first hospital in the U.S

Advanced Catheter Therapies Receives Second FDA 510(k) Clearance on Occlusion Perfusion Catheter
Advanced Catheter Therapies, Inc. (ACT) (www.acatheter.com), today announced that its Occlusion Perfusion Catheter™ (OPC) has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The patented OPC is a universal targeted therapeutic agent delivery catheter

Advanced Catheter Therapies' OPC Device Featured in Live Case at NCVH
The Occlusion Perfusion Catheter™ (OPC), a FDA-approved multi-lumen balloon catheter providing targeted intravascular drug delivery, was featured in a live case presentation during the 16th Annual New Cardiovascular Horizons (NCVH) Conference. Frank T. Bunch, M.D., F.A.C.C

Indraprastha Apollo Hospitals Organises the 7th Asia Pacific Vascular Intervention Course
Business Wire IndiaThe 7th Asia Pacific Vascular Intervention Course, under the aegis of Indraprastha Apollo Hospital, New Delhi, was organized in association with International Society of Endovascular Specialists, USA at The Oberoi, New Delhi from 12th to 14th June, 2015

Miami Dade College Names Bioheart CEO, Mike Tomas, to Board of Advisors for New Idea Center
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomás, President and CEO, will sit on the board of advisors for Miami Dade College's new Idea Center which will serve as Miami Dade College's hub for entrepreneurship for its 165,000 students

Bioheart Announces Partnership in Colombia
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces partnership to bring Bioheart regenerative therapies to Colombia.

Bioheart Announces Positive 12 Month Preliminary Data From Phase I Angel Trial
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, released today preliminary 12 month data from its phase I ANGEL Trial

Bioheart Announces Successful Grand Opening of Facility in South Africa
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to United States regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces a successful grand opening of the laboratory and clinic in South Africa.

LENSAR Appoints Peter J. Mariani as Chief Financial Officer
LENSAR Inc., a global leader in next-generation femtosecond laser technology for refractive cataract surgery, today announced the appointment of veteran financial executive Peter J. Mariani as Chief Financial Officer, effective July 8, 2014. He will report to Nicholas Curtis, LENSAR's Chief Executive Officer.

Bioheart Announces Grand Opening of Facility in South Africa
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announces the grand opening the laboratory and clinic in South Africa.

Bioheart Releases Q2 Financial Information Showing Growth
Bioheart, Inc. (OTCQB: BHRT) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.

Bioheart Announces World's First Combination Stem Cell Treatment
Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell™ or adipose derived stem cells and MyoCell® or muscle derived stem cells

Bioheart Announces Grand Opening of Magnum Cell Therapies
Bioheart, Inc. (OTCQB: BHRT) announced today that it will participate in the grand opening event of Magnum Cell Therapies (Magnum) in Honduras during the week of July 21st. Bioheart has previously announced the joint venture with Magnum and the goal to bring regenerative therapies to patients in South America.

Bioheart Announces Clinical Trials in India
Bioheart, Inc. (OTCQB: BHRT) announced today that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell™ or adipose derived stem cells

Bioheart Announces Joint Venture in South Africa
Bioheart, Inc. (OTCBB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Dr. Walter Bell of South Africa.

Bioheart to Present at the PRP and Regenerative Medicine Symposium (TOBI 2014)
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 5th annual PRP & Regenerative Medicine Symposium on June 6-7 (TOBI 2014)

Bioheart to Present at the World Stem Cells & Regenerative Medicine Congress
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 9th annual World Stem Cells & Regenerative Medicine Congress on May 20th-21st, 2014 in London, England

Bioheart Reports Significant Revenue Increases
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today its financial results for the first quarter of 2014.

Bioheart to Present at 22nd Mediterranean Conference of Medicine and Therapeutic Cosmetic Surgery
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 22nd Mediterranean Conference of Medicine and Therapeutic Cosmetic Surgery in Barcelona, Spain, May 16th-18th, 2014.

Bioheart, Inc. Announces Update on Phase I Adipose Stem Cell Trial
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.

Bioheart, Inc. Presented Clinical Trial Results at the Age Management Medicine Group Conference
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, presented at the 16th Clinical Applications for Age Management Medicine Group conference and Scientific Seminar in Orlando, Florida April 24-27.

Bioheart Announces Clinical Study for Chronic Obstructive Pulmonary Disease
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a new study for chronic obstructive pulmonary disease (COPD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell™ in patients with COPD.

Bioheart, Inc. to Present Clinical Trial Results at the Age Management Medicine Group Conference
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 16th Clinical Applications for Age Management Medicine Group conference and Scientific Seminar in Orlando, Florida April 24-27

Schools Lead Fight Against Diabetes

Hansen Medical to Exhibit Magellan(TM) Robotic System at Vascular InterVentional Advances Conference
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will exhibit its Magellan™ Robotic System at the Vascular InterVentional Advances (VIVA) conference, from October 8-11 at the Wynn Hotel in Las Vegas. The Company will be conducting product demonstrations and exhibiting the Magellan Robotic System at Booth 212.

Bioheart, Inc. to Present at Vail Symposium's Winter Program on Cell Therapy
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the Vail Symposium Winter Program on stem cells on January 10, 2014.

Bioheart Reports Update on CEO
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, reports that Mike Tomas, president and CEO, underwent emergency surgery yesterday and is recovering well and on schedule.

Bioheart Announces Clinical Study for Dry Macular Degeneration
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a study for dry macular degeneration. The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell™ in patients with dry macular degeneration.

Bioheart, Inc. Enters Into Investment Banking Agreement With Cassel Salpeter & Co.
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development, and commercialization of autologous cell therapies, has entered into an investment banking agreement with Cassel Salpeter & Co. as its exclusive financial advisor in connection with investment banking matters

Bioheart Announces Agreement With StemMD to Provide Bioheart Therapies to Its Network
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it has entered into an agreement with StemMD. According to the agreement term sheet, StemMD will provide Bioheart therapies to its global network of physicians and qualified patients.

Bioheart Announces New Clinical Site in Mexico
Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico

Bioheart's President/CEO Mike Tomas Named Chair of the eMerge Innovate Advisory Board of eMerge Americas
Bioheart, Inc. (OTCQB: BHRT) President/CEO Mike Tomas has been named Chair of the eMerge Innovate Advisory Board of eMerge Americas, a technology showcase to take place in Miami Beach, Florida, May 2-6, 2014

NuPathe Announces Third Quarter 2013 Financial Results and Recent Operational Highlights
NuPathe Inc. (NASDAQ: PATH) today announced financial results for the quarter ended September 30, 2013, as well as recent operational highlights.

Bioheart Announces Agreement With Global Stem Cell Group to Provide Bioheart Therapies and Training
Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies to treat cardiovascular disease, has announced an agreement with Global Stem Cells Group, Inc. of Miami to provide Bioheart therapies and products to its worldwide network of physicians and qualified patients.

Bioheart Announces Agreement With Anosis to Distribute Products in the Middle East
Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease announces that it has entered into an agreement with Anosis, a company organized in Turkey

Bioheart Announces Contract With African-Middle East Medical (AFRIMID) to Begin Distributing Stem Cell Products in Uganda
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today it has signed a contract with African-Middle East Medical (AFRIMID) to implement Bioheart therapies for the more than 36 million patients in Uganda

Bioheart Adds Two Service Providers to Its Team of Resources
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, has enhanced its resources with the addition of two service providers on its team -- Outside Eyes and Mitrani, Rynor, Adamsky & Toland, P.A.

Bioheart Announces Positive Preliminary Data From Phase I ANGEL Trial
Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, announced today preliminary data from its phase I ANGEL Trial

Bioheart Announces Agreement With Invitrx to License Adipose Derived Stem Cells
Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease announces that it has entered into an agreement with Invitrx Therapeutics to license their adipose derived stem cell products

NuPathe Doses Adolescent Migraineurs in Clinical Study of ZECUITY
NuPathe Inc. (NASDAQ: PATH) today announced the Company has initiated dosing of patients for NP101-015, a Phase 1 study of ZECUITY® (sumatriptan iontophoretic transdermal system) in adolescents with a history of migraine attacks. This open label, single-dose study will assess the safety, pharmacokinetics, and tolerability of ZECUITY in adolescent migraine patients

Bioheart Boosts Team With Regulatory, Finance and Administrative Expertise
Bioheart (OTCQB: BHRT), a leader in developing stem cell therapies to treat cardiovascular diseases, has expanded its team by adding three key strategic positions with regulatory, finance and administrative expertise.

Sheldon T. Anderson Elected to the Board of Directors of Bioheart, Inc.
Sheldon T. Anderson has been elected to the Board of Directors of Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease. Mr. Anderson is Chairman of the Advisory Board of Northern Trust

Bioheart's President / CEO Mike Tomas Appointed to Workforce Florida Board of Directors by Governor Rick Scott
Bioheart, Inc. (OTCQB: BHRT) announced today that Mike Tomas, the company's President/CEO, has been appointed to serve on Workforce Florida's Board of Directors for a four year term by Florida Governor Rick Scott. Tomas is one of 15 Floridians appointed to the Board of Directors

Bioheart Receives Validated FDA Registration for Tissue Bank Establishment
Bioheart, Inc. (OTCQB: BHRT) announced today that it received a validated registration from the FDA for the initial tissue bank listing. Bioheart is offering stem cell storage for patients enrolled in the studies at the centers of excellence outside the US. This new business unit will create an additional revenue stream for Bioheart

Bioheart in Partnership With NorthStar on Physician Training in Stem Cell Techniques
Bioheart Inc. (OTCQB: BHRT) previously announced that it is working with NorthStar Biotech to help promote regenerative medicine. NorthStar has announced that it will subsidize physicians to participate in the Ageless Regenerative Institute stem cell training program

Update: Bioheart Partnership With Stemlogix Leads to First in U.S. Combination Regenerative Medicine Treatment on Injured Horse
Bioheart Inc. (OTCQB: BHRT) previously announced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market. Stemlogix has just announced the first ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

Bioheart Partnership With Stemlogix Leads to First in U.S. Combination Regenerative Medicine Treatment on Injured Horse
Bioheart Inc. (BHRT.QB) previously announced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market. Stemlogix has just announced the first ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

Bioheart to Initiate ANGEL Trial in Mexico
Bioheart, Inc. (OTCQB: BHRT) has announced that it will initiate its ANGEL trial in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). NorthStar Biotech LLC, a consortium of Bioheart Directors and Shareholders, has agreed to fund the trial which will test the safety and efficacy of LipiCell™ (adipose derived stem cells) in congestive heart failure patients

Bioheart Extends Licenses of Electrical Stimulation Patents With Airspeed
Bioheart, Inc. (OTCQB: BHRT) today announced that they have agreed to extend the license agreement with Airspeed for four separate Bioheart patents. The patents include methods of electrical stimulation and biological pacing, which are marketed under the MyoStim™ product line

NorthStar Launches $20 Million Private Placement Round With Proceeds to Fund Bioheart Trials
NorthStar Biotech, LLC, a consortium of Bioheart, Inc. (OTCQB: BHRT) Directors and Shareholders, led by Managing Director Chuck Hart, has launched a series A private placement financing round and intends to raise a maximum capital of $20 million in exchange for 30% of the company.

Bioheart Presents at AABB Conference in Boston
Bioheart, Inc. (OTCQB: BHRT) presented at the 2012 annual AABB (formerly the American Association of Blood Banks) conference in Boston, MA. Bioheart's Chief Science Officer, Kristin Comella, was invited to present about autologous adult cell-based therapies in a section directed by the International Cellular Medicine Society (ICMS)

Interface Biologics Announces Licensing Partner AngioDynamics has Received FDA Clearance for BioFlo(TM) PICC with Endexo(TM) Technology
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that AngioDynamics has been granted 510(k) clearance by the U.S. Food and Drug Administration for its BioFlo PICC with IBI's Endexo technology. These vascular access products are expected to launch in the U.S

Bioheart Renegotiates Company Note With Favorable Terms
Bioheart, Inc. (OTCBB: BHRT) has renegotiated the terms of a Company note in the amount of $572,000 held by NorthStar Biotech, LLC, a consortium of Bioheart Directors and Shareholders, led by Bioheart Director Chuck Hart. To preserve cash, NorthStar has agreed to suspend the requirement of principal payments by Bioheart and to allow payment of interest-only in restricted stock.

Bioheart Receives $ 2 Million Term Sheet Investment Offer From Vitalmex, a Global Leader in Healthcare in Latin America and Europe
Bioheart, Inc. (OTCBB: BHRT) announced today it has received a non-binding term sheet and investment offer in the amount of $ 2 million from Grupo Vitalmex in Mexico, a global leader in the healthcare sector in Latin America and Europe. (www.vitalmex.com.mx).

Make Your Feet Happy
(Family Features) With more than 26 bones, 33 joints and more than one hundred muscles, tendons and ligaments, the human foot is quite a complicated piece of anatomy. A lot of people take their feet for granted -- until they start to hurt. Unfortunately, most people will have to deal with painful feet at some time.

New Epidemiological Data Provide Additional Safety Evidence for Lantus(R)

Sanofi Announces Results of ORIGIN, the World's Longest and Largest Randomized Clinical Trial in Pre- and Early Diabetes
Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), which showed that Lantus® (insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period

Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabetics Significantly Reduced HbA1c and Post-Prandial Glucose

Lantus(R) Initiation After Metformin Achieved Superior Glycemic Control Versus Sitagliptin in Type 2 Diabetes
Sanofi (EURONEXT: SAN) (NYSE: SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c -- glycated hemoglobin -- reduction with Lantus® (insulin glargine [rDNA origin] injection) versus sitagliptin

Hydromer's Hydrophilic Coating on Jotec's EndoVascular Implant Placement Devices
Hydromer, Inc. (OTCQB: HYDI) (PINKSHEETS: HYDI) and Jotec GmbH have entered into a Supply and Support Agreement.

Hansen Medical to Exhibit Its Magellan(TM) Robotic System at Major European Meeting of Vascular Surgeons
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it will showcase its Magellan™ Robotic System at the 34th Annual Charing Cross International Symposium from April 14-17 in London.

A Forward Look, the Year Ahead - Featured Research on Crosstex Energy, Inc. and CVR Energy, Inc.
Today, www.BollingerReport.com introduced featured coverage of Crosstex Energy, Inc. (NASDAQ: XTXI) and CVR Energy, Inc. (NYSE: CVI). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=XTXI&sm2=CVI.

Living alone raises risk of death
Living alone may increase risk of mortality, cardiovascular death, according to a new study.

Blood pressure difference in both arms 'could signal heart risk'
Differences in systolic blood pressure between arms could be a useful indicator of the likelihood of vascular risk and death, scientists have said.

Hansen Medical to Showcase Magellan(TM) Robotic System at Multidisciplinary European Endovascular Therapy Congress
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it will showcase its Magellan™ Robotic System at the Multidisciplinary European Endovascular Therapy (MEET) Congress, from December 1-3, at the Crowne Plaza St. Peter's Hotel in Rome, Italy

Despite Recession, Medical Device Development Group Continues to Thrive
Medical Device Development Group (MDDG) is celebrating its fifth anniversary, having not only survived the recession, but actually thrived. The company, which is focused on medical devices, provides comprehensive product development as well as resources that extend from product conceptualization, through prototyping and manufacturing, to order fulfillment.

Hansen Medical to Exhibit Magellan(TM) Vascular Robotic System at National Meeting of Vascular Surgeons
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it will exhibit for the first time in the U.S

Hansen Medical Submits 510(k) Application With U.S. FDA for Vascular Robotic System and Catheter
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced that it has submitted a 510(k) pre-market notification application with the U.S. Food and Drug Administration (FDA) on its Vascular Robotic System and Catheter.

Hansen Medical Announces First Ever Public Exhibit of Its Vascular Robotic System at Key European Meeting of Vascular Surgeons
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it will exhibit its Vascular Robotic System at the 33rd Annual Charing Cross International Symposium from April 9-12 in London, U.K. The Company will be exhibiting its Vascular Robotic System at Stand 415.

US WorldMeds Announces Launch of ALSUMA(TM) (sumatriptan injection) 6 mg/0.5 mL Auto-Injector for Subcutaneous Use
US WorldMeds, LLC, announced today that it has launched the recently Food and Drug Administration-approved ALSUMA™ Auto-Injector, which is indicated for the acute treatment of migraine attacks with or without aura, and cluster headache episodes

Patients' own stem cells successfully used to cure clogged arteries
Surgeons from the University of Louisville have successfully performed the first three prosthetic bypass graft surgeries using the patient's stem cells to treat peripheral vascular disease (PVD).

Diet soda ups risk of vascular events; high salt intake linked to stroke
Two separate studies have found that drinking diet soda may raise odds of vascular events and high salt consumption is associated with risk of ischemic strokes.

Understanding causes of insulin resistance
Insulin is a hormone that is produced by the beta cells, which are cells that are scattered throughout the pancreas. The insulin produced is released into the blood stream and travels throughout the body. Insulin is an important hormone that has many actions within the body

Comment on this story

Share